Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
08:31am, Friday, 01'st Aug 2025
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo
President Trump demands drugmakers slash prices within 60 days
06:54am, Friday, 01'st Aug 2025
CNBC's Joe Kernen reports on the latest news.
Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use
04:30pm, Thursday, 31'st Jul 2025
Leqvio can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in patients with hypercholesterolemia (high LDL-C)1 4 out of 5 atherosclerotic car
Trump pressures 17 pharma CEOs to cut US drug prices
02:28pm, Thursday, 31'st Jul 2025
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
01:48pm, Thursday, 31'st Jul 2025
President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a cont
Here's Why Novartis (NVS) is a Strong Value Stock
10:41am, Thursday, 24'th Jul 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:51am, Thursday, 24'th Jul 2025
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Novartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapies
08:11am, Thursday, 24'th Jul 2025
Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several inflammatory diseases.
Matchpoint to receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential payments, including option exercise fee, development and commercial milestones
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
10:46am, Monday, 21'st Jul 2025
J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.
Novartis AG (NVS) Q2 2025 Earnings Call Transcript
02:50am, Monday, 21'st Jul 2025
Novartis AG (NYSE:NVS ) Q2 2025 Earnings Conference Call July 17, 2025 8:00 AM ET Company Participants Harry Kirsch - Chief Financial Officer Sloan Simpson - Global Head of Investor Relations Vasant N
Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.
10:49am, Sunday, 20'th Jul 2025
President Donald Trump's trade policies have caused tumult on Wall Street. The president has pushed for aggressive tariffs on imported goods in an attempt to bring manufacturing jobs back to the count
Buy These 5 Low-Leverage Stocks Amid Impressive Retail Sales Data
11:26am, Friday, 18'th Jul 2025
With retail sales rebounding and Wall Street gaining, low-leverage stocks like NVS, RMD, WAB, ESLT and INGR offer scope for upside.
Uber & Lucid deal, Alcoa & Novartis CEOs talk earnings
05:03pm, Thursday, 17'th Jul 2025
Here is what you may have missed on Market Catalysts for Thursday, July 17. Uber and Lucid are partnering on a new robotaxi service.
